Definium Therapeutics (formerly MindMed) is a biotech company forging a new era of psychiatry by applying precision to psychedelic medicine. We develop science-led, accessible treatment approaches designed to open new routes for brain health and help people reclaim more vibrant lives. From day one, we have been powered by a radical idea: treatments for anxiety and depression should bring real relief.
Together we’re moving psychiatry forward— beyond better, into a boundless future.
Definium Therapeutics trades on the NASDAQ under the symbol DFTX.
Industry: Biotechnology Research
Company Size: 51-200 employees